A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Trial Profile

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2017

At a glance

  • Drugs Crisaborole (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Anacor Pharmaceuticals
  • Most Recent Events

    • 03 Dec 2017 Results of a study assessing safety and efficacy of crisaborole ointment using patient data from AD-301 and AD-302 trials published in the British Journal of Dermatology
    • 14 Dec 2016 According to a Food and Drug Administration media release, The U.S. Food and Drug Administration has approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older.
    • 13 Jul 2016 Results published in the online issue of the Journal of the American Academy of Dermatology, as per Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top